Faron Pharmaceuticals has attracted renewed attention afterLSE:FARN gained 9.51% on 28 September 2026.
Verici Dx has attracted renewed investor attention afterLSE:VRCI rose 11.11% on 28 September 2026.
On 25 September 2026, Avacta Group plc published an update headed "Further Demonstration of Potential of AVA6103". The announcement coincides with preclinical data presented at the AACR Conference on Pancreatic Cancer, held in San Diego, California, from 25 to 28 September 2026.
On 25 September 2026, Thalia Therapeutics plc announced that its RNA gene-silencing cardiovascular programme had advanced. The company said it has "completed the initial chemistry synthesis of the siRNA gene-silencing medicines for its cardiovascular programme, THAT-002."
KITS (TSX:KITS) placed No. 221 overall and No. 25 in the Consumer category. The ranking is based on three-yearRevenuegrowth, and KITS reported growth of 121 per cent over that period, meaning it more than doubled its revenue in three years.
On 25 September 2026, Abingdon Health announced the official opening of its manufacturingFacilityin Madison, Wisconsin. The event took the form of a ribbon-cutting ceremony attended by company executives and local and state officials.
TheBusinessdid not collapse. Hikma remains profitable and cash-generative, with more than $3bn of annual revenue. What changed was the market's view of how fast it can grow, especially in US injectables. It was not promoted back in the September 2026 review.
Covalon operates in the healthcare technology space, with itsBusinessfocused on technologies and products designed to address wound care, infection prevention and other medical applications. For investors following smaller healthcare companies, the key question is whether commercial expansion and product adoption can eventually translate into …
That review has now reached its end point. The CMA published its final report on 24 March 2026 and its final order on 22 September 2026, with the first measures due to apply to larger practice groups from 23 December 2026. Two days after …
The US, the market that matters most, is further back in the queue. The Food and Drug Administration approved the gene edit in April 2025, and Canada followed in January 2026. Genus has said that successful commercialisation in North America also requires approvals in …